In an effort to improve the diagnosis of PCOS, the 2023 International Evidence-Based Guidelines has recommended that serum anti-Mullerian hormone (AMH) could be used in lieu of ultrasound for defining PCOS, in conjunction with the pre-existing diagnostic algorithm [1]. Here, AMH is linked to polycystic ovary syndrome.